Sialomucin complex (SMC, rat Muc4) is a membrane mucin implicated in the protection of epithelia and the metastasis of some tumors. It is a heterodimeric complex, containing a mucin subunit with anti-adhesive activity and a transmembrane subunit with epidermal growth factor-like domains, one of which acts as an intramembrane ligand for ErbB2. Serum, insulin and insulin-like growth factor, but not epidermal growth factor, induce the expression of sialomucin complex in mammary epithelial cells. Induction correlates with sustained, but not transient, activation of extracellularregulated protein kinase (ERK). MEK inhibitor U0126 blocked the induction, while activated MEK-1 transfected into a rat mammary adenocarcinoma cell line induced a sustained activation of ERK and up-regulated SMC/Muc4 expression. Northern and Western blotting indicated that up-regulation occurred concomitantly at the transcript and protein levels, both of which could be blocked by U0126. These results suggest that expression of SMC/Muc4 in mammary epithelial cells is regulated by selected growth factors through an ERK-dependent pathway at the transcript level. Oncogene (2000) 19, 4354 ± 4361.
Introduction
Sialomucin complex (SMC) is a membrane glycoprotein complex isolated from highly metastatic 13762 rat mammary adenocarcinoma cells and composed of an O-glycosylated mucin subunit ASGP-1 (ascites sialoglycoprotein-1) and an N-glycosylated integral membrane glycoprotein subunit ASGP-2 . The latter has two epidermal growth factor-like domains and can act as an intramembrane ligand and modulator of the receptor tyrosine kinase ErbB2 . SMC is transcribed from a single gene as a 9-kilobase transcript (Sheng et al., 1992) and translated into a single &300 kDa polypeptide, which is proteolytically cleaved into the two associated subunits early in its transit to the cell surface . Mature glycosylated ASGP-1 has a molecular mass of 4500 kDa, with a polypeptide molecular mass of &220 kDa, and comprises three domains (Wu et al., 1994) : an Nterminal unique sequence, a large tandem repeat region rich in serine and threonine residues similar to that of other mucins, and a C-terminal unique sequence. ASGP-2 is a 120 ± 140 kDa protein containing seven domains: two hydrophilic N-glycosylated regions, two epidermal growth factor (EGF)-like domains, a cysteine-rich domain, a transmembrane domain, and a small cytoplasmic domain (Sheng et al., 1992) . Recently, it was demonstrated that the N-terminal amino acid sequence of ASGP-1 and the complete sequence of ASGP-2 from rat SMC are 60 ± 70% identical to the sequence of human MUC4 (Moniaux et al., 1999) , which contains all of the domains of ASGP-2. Rat SMC diers from human MUC4 by the absence of a 16-amino acid tandem repeat, which was the original identifying characteristic of MUC4 (Porchet et al., 1991) . In this presentation, we will use the hybrid term SMC/Muc4.
In tumor cells SMC/Muc4 may have multiple functions. (1) ASGP-1 can provide anti-recognition and anti-adhesive properties to tumor cells , which protect them from killing by natural killer cells and promote their metastasis (Komatsu et al., 2000) . (2) The two EGF-like domains of ASGP-2 have all of the consensus residues present in active members of the EGF growth factor family (Sheng et al., 1992) ; ASGP-2 has been shown to bind and modulate the receptor tyrosine kinase ErbB2 . The interaction between ASGP-2 and ErbB2 may play a role in the constitutive phosphorylation of ErbB2 in the 13762 ascites cells (Juang et al., 1996) and in tumor progression of mammary tumors . SMC/Muc4 is expressed in a number of normal secretory epithelial tissues in the adult rat, including the mammary gland (Rossi et al., 1996) , small and large intestine (Rossi et al., 1996; McNeer et al., 1997) , uterus (McNeer et al., 1998a) , and trachea (McNeer et al., 1998b) , and is probably involved in multiple functions in these organs (McNeer et al., 1997) . In mammary gland, SMC/Muc4 is developmentally regulated (Price-Schiavi et al., 1998) . It is abundant in milk and lactating mammary gland, but its level is low in the virgin gland. RNA analyses indicate that this dierential results from a post-transcriptional eect, since mammary gland RNA levels are similar in virgin and pregnant animals (Price-Schiavi et al., 1998) . Upon removal from virgin rat, epithelial cells of mammary glands in culture produce SMC/Muc4, which suggests mammary epithelial cells of virgin rats have the potential to make SMC/Muc4 but their in vivo microenvironment prevents them from doing so. In support of this proposal, the reconstituted basement membrane Matrigel and transforming growth factor-b (TGFb) are able to negatively regulate expression of SMC/Muc4 in vitro by post-transcriptional mechanisms (Price-Schiavi et al., 1998 , 2000b .
Although SMC/Muc4 expression is largely posttranscriptionally regulated in the mammary gland, there must be a mechanism in vivo for inducing and maintaining expression of SMC/Muc4. In previous studies we have shown that serum stimulates the expression of SMC/Muc4 in isolated mammary epithelial cells (Price-Schiavi et al., 1998) . To investigate the factors and pathways involved in this stimulation, we have examined the eect of several serum factors as well as inhibitors and activators of signaling pathways. The results demonstrated the ability of insulin and IGF to upregulate SMC/Muc4 expression at the transcript level. Furthermore, the extracellular-regulated protein kinase (ERK) subfamily of MAP kinases were shown to be involved in the eects of these factors. Together with previous studies of TGFb post-transcriptional downregulation of SMC/Muc4, these results indicate that SMC/Muc4 expression is tightly regulated in mammary gland.
Results

Time course of SMC/Muc4 induction in cultured rat mammary epithelial cells (MEC)
Epithelial cells from virgin rat mammary gland express low levels of SMC/Muc4 protein. We had previously shown that MEC cultured in the presence of 10% fetal calf serum (FBS) have substantially higher levels of SMC/Muc4 than those cultured under serum-free conditions (Price-Schiavi et al., 1998) . To determine the timing of SMC/Muc4 induction by serum, MEC were isolated from virgin rats and cultured on plastic in Ham's F-12 medium supplemented with 10% FBS. Cells were harvested at times ranging from 0 to 48 h and were analysed by immunoblotting with mAb 4F12, which recognizes the transmembrane subunit ASGP-2 of SMC/Muc4 (Rossi et al., 1996) . In all tissues studied to date, including the mammary gland (Rossi et al., 1996) , we have found ASGP-1 and ASGP-2 together in a complex and thus, we assay for ASGP-2 as a marker for SMC/Muc4. Freshly isolated MEC had low levels of SMC/Muc4, as expected. SMC/Muc4 levels began increasing between 3 and 6 h and increased steadily up to at least 48 h (Figure 1 ). These data suggest that one or more factors in serum are involved in maximal induction of SMC/Muc4 protein levels.
Effect of exogenous factors on SMC/Muc4 levels in normal MEC
To determine which factors in serum may be involved in the upregulation of SMC/Muc4, primary mammary epithelial cell cultures were treated with a number of factors demonstrated to have an eect on mammary gland development or dierentiation. MEC were isolated and cultured as described in the presence or absence of each factor for 48 h, followed by immunoblot analysis with anti-ASGP-2 mAb 4F12. Basal levels of SMC/Muc4 protein were determined from MEC cultured in media alone. Fetal bovine serum (FBS) had the largest eect, increasing SMC/Muc4 protein levels by 27-fold, as expected from the large number of components in serum that can potentially act additively to upregulate SMC/Muc4. Individually, insulin and IGF-1 were able to enhance SMC/Muc4 levels by approximately 6 ± 7-fold and may play a signi®cant role in the eect of FBS (Figure 2a) . However, growth factors EGF, TGFa, and NDF had no eect on SMC/ Muc4 levels in this system, even though these have been shown to play a role in mammary gland development and dierentiation (Coleman and Daniel, 1990; Spitzer et al., 1995; Marte et al., 1995) . Although estrogen and progesterone have been shown to aect SMC/Muc4 levels in the uterus (McNeer et al., 1998a) , neither hormone aected SMC/Muc4 in cultured MEC. Hydrocortisone was the only hormone observed Cells were harvested at times ranging from 0 to 48 h as indicated at the bottom of the ®gure, and 15 mg total protein for each time point analysed by immunoblotting with mAb 4F12 Figure 2 Eect of IGF-1 and insulin on SMC/Muc4 expression in normal cultured MEC. Cultured MEC were treated with 50 ng/ ml IGF-1, 5 mg/ml insulin, or 10% FBS for 24 h. Cells were extracted and analysed by immunoblotting with anti-ASGP-2 mAb 4F12, anti-ERK, or anti-phospho-ERK antibodies, or by the ERK kinase assay, as indicated at the right of the ®gure to have a signi®cant positive eect, increasing SMC/ Muc4 levels by approximately 12-fold. Enhanced levels of SMC/Muc4 in cells treated with IGF-1 or insulin suggest that these factors are speci®cally involved in the regulation of SMC/Muc4 expression in normal rat mammary gland. The lack of SMC/Muc4 response to other factors tested suggests that either they are not involved in SMC/Muc4 regulation or that they are part of larger, more complex pathways that may require synergistic actions with other components or cellular interactions with the surrounding mammary stroma.
Effects of signal transduction pathway inhibitors on SMC/Muc4 expression in normal MEC
We have shown that SMC/Muc4 is regulated largely by post-transcriptional mechanisms during the reproductive cycle in normal rat mammary gland (Price-Schiavi et al., 1998 , 2000b . However, there must be a regulatory mechanism to initiate and maintain production of SMC/Muc4 message prior to pregnancy and in MEC. To address this issue, inhibitors and activators of three types of signaling pathways, tyrosine kinase, protein kinase C, and cyclic AMP, were used to determine if these pathways modulated SMC/Muc4 expression in MEC in vitro. MEC were isolated and cultured in Ham's F-12 supplemented with insulin, transferrin, sodium selenite, or 10% FBS and each of the inhibitors to determine what eect, if any, each would have on FBS or insulin stimulation of SMC/ Muc4 protein levels in the MEC. After 24 h cells were harvested and 5 mg total cell protein were subjected to immunoblot analysis with mAb 4F12. SMC/Muc4 protein levels for each treatment were compared to SMC/Muc4 levels from untreated cells cultured under otherwise similar conditions. Thus, treated cells cultured in insulin, transferrin and sodium selenite were compared to untreated cells cultured in the same conditions. SMC/Muc4 levels were reduced by greater than 75% in cells treated with staurosporine, a promiscuous protein kinase inhibitor with eects on protein kinase C, protein kinase A, and tyrosine kinases (Tamaoki et al., 1986) . Tyrphostin A23, a more speci®c inhibitor of tyrosine kinases that acts on their substrate sites (Levitski et al., 1991) also inhibited SMC/Muc4 expression by greater than 75%. However, genistein, which inhibits tyrosine kinases by binding to the ATP-binding site (Akiyama et al., 1987) , had no eect on SMC/Muc4 levels under these conditions. Northern blot analysis of total RNA extracted from cells treated with staurosporine revealed that this inhibitor also reduces SMC/Muc4 transcript levels (data not shown). The protein kinase C activator phorbol 12-myristate 13-acetate had no eect on SMC/Muc4 levels. None of the agents that elevate cellular cyclic AMP, dibutyryl cyclic AMP, forskolin, and isobutylmethylxanthine, had an eect on SMC/ Muc4 levels. Finally, neither sodium vanadate nor okadaic acid, which inhibit protein phosphatases, had any eect on SMC/Muc4 levels in these assays. Taken together, these data suggest that the signaling pathway(s) regulating basal SMC/Muc4 expression requires tyrosine phosphorylation and does not seem to involve some protein phosphatases. Because of the possibility of synergistic interactions, we cannot at the present time rule out the possibility that the protein kinase C/A pathways may be involved in SMC/Muc4 expression in these cells.
Role of ERK signaling pathway in expression of SMC/Muc4
Up-regulation of SMC/Muc4 initiated by FBS, IGF-1 and insulin correlated with activation of the ERK subfamily of MAP kinases (Figure 2b ). MEC were isolated and treated with either FBS, IGF-1, or insulin. Cells were then analysed for SMC/Muc4 expression by immunoblot analysis with mAb 4F12 and for ERK activity by an an ERK kinase assay or by immunoblot analyses with anti-phospho-ERK and anti-ERK. Cells treated with FBS had the highest levels of SMC, while cells cultured under serum-free conditions had the lowest (Figure 2a ). Cells treated with IGF-1 or insulin had intermediate levels of SMC. All of the cultured MEC express ERK-1 and ERK-2; however, ERK-1 and ERK-2 were activated (phosphorylated) only in cells treated with FBS, IGF-1, or insulin. ERK-1 and ERK-2 were not activated (phosphorylated) in control cells cultured under serum-free conditions. We were unable to detect any activity of p38 in MEC cultured under these conditions (data not shown). These data suggest that IGF-1 and/or insulin signaling through the ERK pathway could be involved in the induction of SMC/Muc4 by FBS.
To determine whether the ERK pathway is involved in up-regulation of SMC/Muc4 by growth factors, virgin MEC were incubated with the MEK-1 inhibitor U0126 at dierent concentrations for 30 min, followed by culture in serum-containing medium for 24 h. U0126 inhibited SMC/Muc4 expression in a dosedependent manner, in parallel with its inhibition of ERK activation (Figure 3a) . To determine if other MAP kinase family members are also involved in regulation of SMC/Muc4 expression, the inhibitory eect of the MEK-1 inhibitor U0126 on SMC/Muc4 expression was compared to that of p38 MAP kinase inhibitor SB203580. Cells were treated under the conditions described above and analysed by immunoblotting with mAb 4F12, anti-ERK, or anti-phospho-ERK antibodies. In contrast to the inhibitory eect of U0126 on both SMC/Muc4 expression and activation of ERK-1 and ERK-2, SB203580 had no eect on SMC/Muc4 expression or ERK-1/ERK-2 activation (Figure 3b) . A control reagent, SB202474, which does not inhibit MAP kinases, also had no eect on SMC/ Muc4 or ERK-1/ERK-2 activation. These data indicate that activation of ERK, but not p38 MAP kinase, is required for up-regulation of SMC/Muc4 by FBS (growth factors).
To determine if activation of the ERK pathway is also involved in induction of SMC/Muc4 by insulin or IGF-1, MEC were treated with U0126 and analysed as described above. In cells treated with either insulin or IGF-1 alone, ERK activity was stimulated and SMC/ Muc4 levels were higher than in untreated cells ( Figure  4) . ERK activity and induction of SMC/Muc4 by insulin or IGF-1 were blocked by treatment with U0126 with no eect on the overall levels of ERK-1 or ERK-2 protein. These data suggest that insulin and IGF-1 are partly responsible for the induction of SMC/ Muc4 by serum, and that activation of the ERK signaling pathway is involved in regulation of SMC/ Muc4 by these growth factors.
Requirement for sustained ERK activity for induction of SMC/Muc4
EGF family members and IGF-1 have been shown to be involved in mammary gland development (Taketani and Oka, 1983a,b; Kleinberg, 1998) . EGF, PDGF, and IGF-1 are all able to activate ERK (Boulton et al., 1991; Cahill and Perlman, 1991; Thomas, 1992) . However, IGF-1 and insulin, but not EGF or PDGF, are able to induce SMC/Muc4 expression in cultured MEC. Signaling through the IGF-1 receptor has been reported to cause sustained activation of ERK, while signaling through the EGF receptor causes only transient activation (Swantek and Baserga, 1999) . To determine whether transient or sustained ERK activation is involved in upregulation of SMC, cultured MEC were treated with either EGF, PDGF, IGF-1, insulin, or serum. Cells were harvested at times ranging from 10 min to 24 h after the beginning of growth factor treatment, and the duration of ERK activation by each of the growth factors was measured by immunoblotting with anti-phospho-ERK. ERK was activated at 10 min by all of the growth factors as well as FBS (Figure 5a ), but ERK activity was sustained for 24 h only in cells treated with IGF-1, insulin or FBS (Figure 5b ). The sustained activation of ERK by IGF-1, insulin or FBS correlates with the induction of SMC/Muc4. To determine what length of sustained ERK activity is required for up-regulation of SMC/ Muc4, cultured MEC were incubated with F-12 medium containing 10% FBS for times ranging up to 9 h. U0126 was added at 3, 6 and 8 h to block ERK activation, and cells were collected and analysed by immunoblotting. Only cells treated with U0126 after at least a 6-h incubation with FBS were able to express higher levels of SMC/Muc4 (Figure 5c ). Thus, ERK activity must be sustained for at least 6 h to achieve maximal induction on SMC/Muc4 by serum.
To demonstrate further that sustained ERK activity will up-regulate SMC/Muc4, hemagglutinin(HA)-MEK-I (S218/222D), a constitutively activated form of MEK-1 carrying an HA epitope tag, was transiently transfected into 13762 MAT-BIII cells, a cultured variant of the 13762 ascites tumor which also express SMC/Muc4 (Figure 5d ). Transfected cells were harvested and analysed by immunoblotting with mAb 4F12, anti-HA, anti-ERK, and anti-phospho-ERK antibodies. When activated MEK-1 was overexpressed, ERK activity and SMC/Muc4 expression were higher than in vector-transfected control cells. The MAT-BIII cells are dicult to transfect, and transfection eciencies tend to be low in these cells. Thus, the increase in SMC/Muc4 expression in cells transfected with the activated MEK-1 would be more evident with higher transfection eciency. Nonetheless, there was an increase in SMC levels in these cells when activated MEK-1 was overexpressed. Taken together these data indicate that sustained ERK activity is involved in upregulation of SMC/Muc4 by serum factors.
ERK signaling pathway and transcript levels of SMC/Muc4
As described above, tyrosine phosphorylation is required for maintenance of both SMC/Muc4 protein and transcript levels, and ERK activity is required for (Figure 6a,b) . However, SMC/Muc4 mRNA was not increased when cells were treated with both serum and U0126. This result suggests that regulation of Muc4 expression by the ERK signaling pathway occurs at least partly by some modulation of the SMC/Muc4 transcript level.
Discussion
Developmental regulation of SMC/Muc4 in normal rat mammary gland is complex, involving several dierent regulatory mechanisms. Among these must be a mechanism to initiate and maintain transcription and basal expression of SMC/Muc4 in the normal animal. We have previously demonstrated post-transcriptional and post-translational mechanisms for negatively regulating SMC/Muc4 protein levels (Price-Schiavi et al., 1998 , 2000b ). Here we report positive regulation of SMC/Muc4 by insulin and IGF-1. Regulation of SMC/ Muc4 by both of these growth factors requires activation of the ERK signaling pathway and aects SMC/Muc4 expression at the transcript level.
Both IGF-1 and insulin have been shown to have important roles in mammary gland development and dierentiation. IGF-1 plays a role in pubertal mammary gland development, most likely by mediating the eects of growth hormone (Kleinberg, 1998) . IGF-1 applied directly to the mammary glands of hypophysectomized, oophorectomized, sexually immature rats simulates substantial ductal growth and terminal end bud formation (Ruan et al., 1992 (Ruan et al., , 1995 . Furthermore, IGF 7/7 mice have signi®cantly reduced mammary development, which can be partially reversed by treatment with IGF-1 (Ruan and Kleinberg, 1999) . There is also a proposed role for IGF-1 in later stages of mammary development. Overexpression of IGF-1 in the mammary glands of transgenic mice during lactation leads to ductal hypertrophy and inhibits involution (Hadsell et al., 1996; Neuenschwander et al., 1996) . Insulin is essential for milk protein gene expression and cell survival in the mammary (7) in F-12 medium containing 0.5% FBS. Twenty-four hours after transfection, cells were collected and extracted. The cell extracts were fractionated by SDS ± PAGE and analysed by immunoblotting with anti-ASGP-2, anti-HA, anti-phospho-ERK and anti-ERK gland. In vitro insulin is required for maintaining mammary tissue in culture and stimulates phosphoprotein synthesis (Voytovich et al., 1969) . Insulin has also been shown to stimulate expression of alactalbumin and b-casein (Nicholas et al., 1983; Prosser et al., 1987) . IGF-1 can similarly stimulate milk protein synthesis but is only about one-tenth as potent as insulin in this regard. Both growth factors have been shown to be equally involved in stimulation of DNA synthesis and inhibition of apoptosis in HC11 mammary epithelial cells (Merlo et al., 1996; Wartmann et al., 1996) . SMC/Muc4 is expressed at low levels in virgin mammary gland, increases sharply during pregnancy reaching maximum levels during lactation, and decreases rapidly during involution (Price-Schiavi et al., 1998) . Although the exact timing is as yet unknown, initiation of SMC/Muc4 expression must occur very early during mammary development because it is detectable in the rudimentary ductal tree (ducts and terminal end buds) of 3-week-old prepubertal female rats (Li and Carraway, unpublished) . In cultured MEC, FBS substantially enhances both SMC/Muc4 protein and mRNA levels, suggesting that some factor or factors in serum may be involved in regulating SMC/Muc4 expression. Of the factors tested under our culture conditions, insulin and IGF-1 could substantially reproduce the increase in SMC/Muc4 levels produced by serum. The presence of IGF-1 and insulin in the mammary gland and their eects on mammary gland development and dierentiation suggest that both of these factors may be involved in initiation and maintenance of SMC/Muc4 expression in normal rat mammary gland. The fact that all three factors (serum, insulin, and IGF-1) stimulate the ERK signaling pathway in a similar manner suggests that insulin and IGF-1 are at least partially responsible for the serum eect.
Inhibition of the ERK pathway by the MEK-1 inhibitor U0126 led to decreased SMC/Muc4 protein and transcript levels. These observations suggest that the ERK signaling pathway (through IGF-1 and/or insulin) is involved in maintenance of SMC/Muc4 expression at the transcript level. The downregulation of SMC/Muc4 transcript with U0126 treatment is not complete after 24 h. This suggests that the SMC/Muc4 message has a slow turnover and/or that regulation of SMC/Muc4 via an ERK dependent pathway also involves post-transcriptional mechanisms. A primary function of the ERK signaling pathway involves the regulation of transcription factors. Downstream targets of ERK-1/2 include ribosomal S6 kinase (RSK) (Waskiewicz and Cooper, 1995) , ternary complex factors (TCFs) such as Elk-1, and signal transducer and activator of transcription (STAT) family members, such as STAT5a (McCawley et al., 1999; Marais, et al., 1993) . Furthermore, RSK has been shown to regulate transcription factors such as c-Fos, estrogen receptor, NF-kB/IkBa, c-AMP-response element-binding protein (CREB) and CREB-binding protein (Frodin and Gammeltoft, 1999) . We have recently cloned and sequenced a putative rat SMC/Muc4 promoter (PriceSchiavi et al., 2000a) . This sequence contains several transcription factor-binding sites, including AP-1, NFkB, CREB and STAT5. Studies are currently underway to determine which, if any, of these sites are involved in regulation of SMC/Muc4 expression downstream of ERK-1/2 activity. Cellular behavior can be determined by the duration of ERK activity. For example, in keratinocyte cell lines, ligands that transiently activate p42/p44 ERK/ MAP kinases are mitogenic but do not induce MMP-9 expression or colony dispersion (McCawley et al., 1999) . On the other hand, ligands that induce sustained activation of these kinases stimulate MMP-9 expression and colony dispersion (McCawley et al., 1999) . For enhancement of SMC/Muc4 levels by serum, sustained activity of ERK is necessary. Although all of the growth factors we tested (IGF-1, insulin, EGF, and PDGF) are capable of activating the ERK pathway, IGF-1 and insulin are the only ones that could elicit sustained activation of ERK-1/2 under these conditions (Boulton et al., 1991; Cahill and Perlman, 1991; Thomas, 1992) . In our culture system, only IGF-1 or insulin, which induce sustained activation of ERK-1/2, could partially mimic the high levels of SMC/Muc4 induced by serum. In contrast, EGF and PDGF, which transiently activate ERK-1/2, could not. Thus, we propose that stimulation of IGF-1 or insulin receptor(s) by IGF-1 or insulin induces sustained activation of ERK, which in turn promotes upregulation of expression of the SMC/Muc4 transcript.
Our combined studies indicate that regulation of SMC/Muc4 in normal mammary gland is very complex. The ERK pathway (serum, insulin, and IGF-1) is part of a complicated equation for , anti-adhesion and ErbB2-modulating mechanisms of SMC/Muc4. Thus, in a sense, the tumor cell is able to`hijack' the mechanism for expression of the milk protein for its own purposes. One of those purposes is likely to use the protective functions of the mucin (McNeer et al., 1997) to protect the tumor cell from being killed by the immune system .
Materials and methods
Materials
U0126 was purchased from Promega (Madison, WI, USA). SB203580, SB202474, actinomycin D, tunicamycin and cycloheximide were from Calbiochem (San Diego, CA, USA). Prolactin and hydrocortisone were purchased from Sigma (St. Louis, MO, USA). Polyclonal and monoclonal (Rossi et al., 1996) antibodies against ASGP-2 were made as previously described. Anti-ERK was purchased from Zymed (South San Francisco, CA, USA). Anti-phospho-ERK was from Promega and Calbiochem. Anti-HA was a gift from Dr Catherine Welsh, University of Miami. TGFb, TGFa, EGF, IGF-1 and insulin were all from R&D Systems (Minneapolis, MN, USA). Plasmid pCMV-HA/Mek-1 (S218/222D) was a gift from Dr Michael Weber, University of Virginia.
Cell culture and transfection
Mammary epithelial cells (MEC) from virgin female Fischer 344 rats were prepared as previously described (Price-Schiavi et al., 1998) and cultured in F-12 medium (or phenol red-free Ham's F-12 when cells were treated with estrogen or progesterone) with FBS, insulin-like growth factor-I, or insulin for indicated times. For experiments with kinase inhibitors and TGFb, freshly isolated MEC were pretreated with the inhibitors in serum-free F-12 medium for 0.5 h and then incubated with F-12 medium containing 10% FBS, IGF-I, or insulin for 24 h. The MAT-BIII cultured subline of the 13762 rat mammary adenocarcinoma was maintained in McCoy's medium with 10% FBS. For transfection, 5610 5 MAT-BIII cells were seeded in 6-well plates on day 1. On day 2, cells were transfected with 2 mg/well of HA-MEK-1 (S218/ 222D) or control vector with lipofectamine (Life Technologies, Inc., Gaithersburg, MD, USA) according to the manufacturer's procedure. Cells were collected and extracted for immunoblotting on day 3.
Immunoblot analyses
MEC and MAT-BIII cells were collected by scraping after the indicated treatment. Cells were extracted in NP-40 buer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM sodium orthorvanadate, 10 mM sodium¯uoride, 1 mM phenylmethylsulfonyl¯uoride, 1/100 diluted protease inhibitor cocktail) as previously described (Zhu and Assoian, 1995; Zhu et al., 1996) . Cell extracts (10 ± 15 mg protein) were analysed in 7.5% polyacrylamide gels with the mini-Protean II system (Bio-Rad, Hercules, CA, USA). Resolved proteins were transferred to nitrocellulose membranes and blocked with 3 ± 5% non-fat milk (Bio-Rad) in TBS with 0.1% Tween-20 and 0.1% sodium azide. The membranes were then probed with ®rst and second antibodies. Proteins were detected by the Renaissance TM Enhanced Chemiluminescence kit (NEN Life Science Products Inc, Boston, MA, USA). For comparisons of SMC/Muc4 protein levels with various treatments, the ASGP-2 (SMC/Muc4) band from each sample was quanti®ed by densitometry and the ratio was taken of ASGP-2 (SMC/Muc4) from the treated versus the untreated samples.
Northern blots
MEC were collected by scraping and extracted in Trizol Reagent (Life Technologies, Inc) according to the manufacturer's procedure. Total RNA (10 ± 15 mg) was electrophoresed on 1% formaldehyde/agarose gels. Fractionated RNA was transferred to Hybond-N nylon membranes (Amersham), followed by cross-linking using a Stratalinker (Stratagene, La Jolla, CA, USA). The membranes were prehybridized for 3 ± 5 h at 428C in prehybridization solution (50% formamide, 1 M NaCl, 26Denhardt's solution, 1% SDS, 0.1 g/ml dextran sulfate, and 0.5 mg/ml salmon sperm DNA). The probes, A2G2-9, a 1.7-kb probe which spans the 5' unique region and four tandem repeats of SMC/Muc4 cDNA, and cDNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were random prime-labeled with 32 P-dCTP using a Random Primed Labeling Kit (Boehringer-Mannheim, Indianapolis, IN, USA). The membranes were hybridized overnight at 428C in prehybridization solution containing labeled probes. Following hybridization, membranes were washed three times at room temperature in 26SSC with 0.1% SDS for 30 min each, and three times at 508C in 0.16SSC with 0.1% SDS for 30 min each. Radioautography was performed on Kodak LS X-ray ®lms (VWR, Atlanta, GA, USA). For comparisons of SMC/Muc4 steady state RNA levels, the SMC/Muc4 band and the GAPDH band from the Northern blot were quanti®ed by densitometry. The ratio of SMC/Muc4 to GAPDH was calculated and the results were plotted.
Immunoprecipitation and in vitro ERK kinase assays
The kinase assay was performed as previously described (Chen et al., 1994) with minor modi®cations. Brie¯y, 50 mg of cell extracts were immunoprecipitated by anti-ERK antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 48C, and the resulting immune complex was incubated with protein A-agarose (Sigma) for an additional 2 h. Immobilized immune complexes were washed twice with 0.25 M Tris, pH 8.0, once with 0.1 M NaCl and 50 mM HEPES, pH 8.0, and once with 25 mM HEPES, pH 8.0, 10 mM MgCl 2 . The immunoprecipitated ERK was incubated with kinase assay mixture (25 mM HEPES, pH 8.0, 10 mM MgCl 2 , 1 mM dithiothreitol, 0.5 mg/ml myelin basic protein, 50 mM ATP, and 10 mCi of [g-32 P]ATP) in a ®nal volume of 30 ml at room temperature for 30 min. The reaction was stopped by adding 30 ml of 26SDS sample buer and boiling for 5 min. The samples were centrifuged, and supernatants were collected for elecrophoresis on a 15% polyacrylamide gel. After staining with Coomassie Brilliant Blue, the gel was dried and exposed to Kodak LS X-ray ®lm at 7708C.
